Author | Kristie L. Kahl


Cabozantinib combo induces clinical activity in advanced ccRCC

September 22, 2020

“The combination of cabozantinib and atezolizumab demonstrated encouraging clinical activity in previously untreated patients with advanced ccRCC,” said investigator Sumanta Kumar Pal, MD.

Novel BiTE immuno-oncology therapy appears safe with preliminary efficacy in mCRPC

September 21, 2020

Treatment with AMG 160 showed a manageable safety profile with preliminary efficacy in patients with metastatic castration-resistant prostate cancer.

Olaparib significantly improves OS in mCRPC subgroup

September 21, 2020

The PARP inhibitor reduced the risk for death by 31% in men with metastatic castration-resistant prostate cancer, compared with enzalutamide or abiraterone plus prednisone.

Testosterone levels show steady decrease among young US men

July 03, 2020

The decline in total testosterone was observed even among men with normal body mass index.